The CLINAM Summit is a globally unique event that brings together all stakeholders in nanomedicine, targeted medicine and precision medicine. Our CEO Santi Sala has participated into the session Presentations on Nanoparticles – Analytics, Methods and Technologies by presenting the work Technology platform for the production of lipid-based nanovesicles as new nanomedicines. By this presentation he has described latest developments related to our projects Nano-Nafres...
Nanomol Technologies has participated in a Nanotechnology Conference applied to Medicine for Health Professionals
This event (June 6th) has been organized by Fundació Althaia, Unió Consorci Fundació and Societat Catalana de Naonociència i Nanotecnologia. https://www.ucf.cat/wp-content/uploads/2018/05/jornada_nanotecnologia_aplicada_a_la_medicina.pdf?mc_cid=0a67fecc7e&mc_eid=b5b475a388
Nanomol Technologies is going to participate in the IQS TECH FEST, the first Festival of industrial Startups
Next January 25th, the festival that will revolutionize the entrepreneurial ecosystem arrives in Barcelona: http://iqstechfactory.com/
Nanomol Technologies has begun its participation in the project Nano-Nafres (COMRDI15-1-0023) that belongs to the RIS3CAT community “Technologies applied to health”. The objective of this project is to perform preclinical and clinical studies on the application of nanoformulated epithelial growth factor in venous ulcers. This project has been cofounded 50% by the European Regional Development Funds from the European Union within the framework of the operative...
Nanomol Technologies is part of the new Horizon 2020 Framework Programme project “Smart-4-Fabry” (Smart multifunctional GLA-nanoformulation for Fabry disease)
The project has started on January 1st, 2017, and will run for 4 years with 10 partners and a budget of 5,800,000 €. The research of Smart-4-Fabry project concerns development of drug delivery systems based on liposomes for treatment of Fabry disease. Advanced formulation and characterization techniques will be used for achieving excellent quality control over the assembly of the different molecular components of a new liposomal nano-formulation which contains the α-Galactosidase A (GLA)...